Epidemiology, pathophysiology and diagnosis of pulmonary arterial hypertension (PAH) in the cirrhotic;Epidemiología, fisiopatología y diagnóstico de la hipertensión arterial pulmonar (HAP) en el cirrótico

Gaceta Medica de Mexico

Volumn 148, Issue 2, 2012, Pages 153-161

  Uribe, Misael ^a   Morales Blanhir, Jaime ^a   Rosas Romero, Reina ^a   Cerda, Ricardo Campos ^a   Poo, Jorge L ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b LIVER RESEARCH UNIT   (Mexico)

Author keywords

Hepatic cirrhosis; Portal hypertension; Porto pulmonary hypertension; Porto systemic gradient; Pulmonary arterial hypertension

Indexed keywords

DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; PORTAL HYPERTENSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SPLANCHNIC BLOOD FLOW; VALVULAR HEART DISEASE; VASCULAR RESISTANCE;

HUMANS; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS; PROGNOSIS;

EID: 84863210111     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-51.
2. Burroughs AK, Thalheimer U. Hepatic Venous Pressure Gradient in 2010: Optimal. Measurement Is Key. Hepatology. 2010;51:1894-96.
3. Badesh DB, Champion HC, Sánchez MA, et al. Diagnosis and Assessment of Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2009;54: S55-66.
4. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219-63.
5. Saleemi S. Portopulmonary hypertension. Ann Thorac Med. 2010;5:5-9.
6. Krowka MJ. Portopulmonary hypertension: diagnostic advances and caveats. Liver Transpl. 2003;32:2177-8.
7. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009:179; 835-42.
8. Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonaryhipertension and the liver transplant candidate. Transplantation. 1999;67:1087-93.
9. Naveau S, Giraud V, Ganne N, et al. Patients with alcoholic liver disease hospitalized in gastroenterology. A national multicenter study. Gastroenterol Clin Biol. 2001;25(2):131-6.
10. Monterrubio D, Marin EL, Larrauri JR, Gusman-Carrera R, Romero M. Epidemiologia de la cirrosis hepatica en la ciudad de Puebla. Rev Gastro Mex 1987 (52)3;175-8.
11. Poo JL, Delgadillo-Torre A, López-Fuerte F, et al. Consenso mexicano sobre diagnóstico y tratamiento de la cirrosis hepática. 02/03/09 [Internet] Disponible en: http://hepatologia.org.mx/LineamientosdelConsensodeCirrosis. pdf.
12. Rodríguez-Hernández H, Jacobo-Karam JS, Castañón-Santillán MC, Arámbula-Chávez M, Martínez-Aguilar G. Supervivencia de pacientes con cirrosis hepática en el Hospital General Regional del IMSS, Durango. Gac Med Mex. 2002;138:325-31.
13. Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol. 2005;4:52-5.
14. McLaughlin V. Classification and epidemiology of pulmonary hypertension. Cardiol Clin. 2004;22:327-41.
15. Lebrec D, Capron JP, Benhamou JP. Primary pulmonary hypertension and portal hypertension. Am Rev Respir Dis. 1979;120:849-56.
16. Portmann R, Stewart S, Higenbottam TW, Clayton PT, Lloyd JK, Williams R. Nodular transformation of liver associated with portal and pulmonary artery hypertension. Gastroenterology. 1993;104: 616-21.
17. Budhiraja R, Hassoun PM. Portopulmonary Hypertension: A Tale of Two Circulation. Chest. 2003;123:562-76.
18. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related. Am Rev Respir Dis 1983;127(4):437-41.
19. Snouber JM, Malik GM. Hepatopulmonary Syndrome and portopulmonary hypertension. JK-Practitioner. 2004;11:60-1.
20. Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. update and diagnostic problems. Mod Pathol. 2000;13:679-704.
21. Rodríguez-Vilarrupla A, Fernández M, Bosch J, García Pagán JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol. 2007;6:28-36.
22. Boyer TD. Portal hypertensive hemorrhage. Pathogenesis and risk factors. Semin Gastrointest Dis. 1995;6:125-33.
23. Kapoor D, Sarin SK. Pathophysiology of portal hypertension. J Gastroenterol Hepatol. 2002;17:S482-7.
24. Comar KM, Sanyal AJ. Portal hypertensive bleeding. Gastroenterol Clin North Am. 2003;32:1079-105.
25. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32:141-56.
26. Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Clin Liver Dis. 1997;1:2-15.
27. Ozaki M, Kawashima S, Yamashita T, et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension. 2001;37:322-7.
28. Morales-Ruiz M, Cejudo-Martin P, Fernández-Varo G. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003;125:522-31.
29. La Villa G, Barletta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology. 2001;34:19-27.
30. Fevery J, Roskams T, Van de Castele M, et al. NO synthase in the liver, prospects of in vivo gene transfer. Digestion. 1998;59 Suppl 2:58-9.
31. Shah V, Totuner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117:1222-8.
32. Reynaert H, Thompson MG, Thomas T. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut. 2002;50:571-80.
33. Montaño LA, Meza JJ. Patogénesis de la hipertensión portal. Rev Invest Clin. 2005;57:596-607.
34. Turder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-32.
35. Deng Z, Morse JH, Slager SL. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67:737-44.
36. Harrison RE, Flanagan JA, Sankela M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary hemorrhagic telangiectasia. J Med Genet. 2003;40:865-71.
37. Boutet K, Montani D, Jaïs X, et al. Therapeutic Advances in Pulmonary Arterial Hypertension. Ther Adv Resp Dis. 2008;2:249-65.
38. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101:927-34.
39. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236-44.
40. Keyes JW, Wilson GA, Quinonest JD. An evaluation of lung uptake of colloid during liver imaging. J Nucl Med. 1973;14:687-91.
41. Alam I, Bass NM, Bacchett P. Hepatic tissue levels of endothelin-1 correlate with severity of chronic liver disease and ascites. Am J Gastroenterol. 2000;95:199-203.
42. Kereveu A, Callebert J, Humbert M. High plasma serotonin levels in primary pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2000;20:2233-9.
43. Beaudry P, Hadangue A, Callbert J. Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology. 1994;20:800-3.
44. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122-8.
45. Saunders JB, Davis M, Williams R. Do women develop alcoholic liver disease more readily than men? Br Med J. 1981;282:1140-3.
46. Hultcrantz R, Glaumann H, Lindberg G. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotranferases. Scand J Gastroenterol. 1989;21:109-15.
47. Smith LG, Camilo ME, Dick R. Percutaneous transhepaticportography in the assessment of portal hypertension. Gastroenterology. 1980;78: 197-202.
48. Treiber G, Csepregi A, Malfertheiner P. The pathophysiology of portal hypertension. Dig Dis. 2005;23:6-10.
49. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardio. 2004;43:40s-7.
50. Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol. 2007;58:591-602.
51. Marius MH, Michael JK, Christian PS. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363:1461-8.
52. Radulescu D, Duncea C, Donca V. Hepatic cirrosis associated with arterial pulmonary hipertensión. Rom J Gastroenterol. 2004;13:341-3.
53. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med. 2008;75:121-36.
54. Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002;20: 1314-31.
55. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6:443-50.
56. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100:520-8.
57. Auletta M, Oliviero U, Iasiuolo L, Scherillo G, Antoniello S. Pulmonary hypertension associated with liver cirrosis: an echocardiographic study. Angiology. 2000;51:1013-20.
58. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 1998;11:1153-66.
59. Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc. 2000;75:625-30.
60. Gaine S. Pulmonary hypertension. JAMA. 2000;284:3160-8.
61. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48:196-203.
62. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST. Distinctive clinical features of portopulmonary hypertension. Chest. 1997;112:980-6.
63. Chan T, Palevsky HI, Miller WT. Pulmonary hypertension complicating portal hypertension: findings on chest radiographs. Am J Roentgenol. 1988;151:909-14.
64. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:201-11.
65. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453-8.
66. Torregrosa M, Genesca J, González A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation. 2001;71:572-4.
67. Swanson KL, Mc Goon MD, Krowka MJ. Survival in portopulmonary hypertension. Am J Respir Crit Care Med. 2003;167:A683.
68. Rodríguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004;24:861-80.
69. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502-8.
70. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124:247-54.
71. Callejas Rubio JL, Salmerón Escobar J, González-Calvin J, Ortego Centeno N. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. Liver Transpl. 2006; 12:690-1.
72. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant. 2005;24: 498-500.
73. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl. 2004;10:945-50.
74. Van der Linden P, Le Moine O, Ghysels M, Ortinez M, Deviere J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology. 1996;23: 982-7.